Biotech Values

[AlpineBV_Miller]

Because of a stupid decision a few years back to whack their R&D, DNDN essentially has no pipeline. Their trp-m8 drug has been in Phase I trials for most of two years with no data. Neuvenge was supposed to start a trial last year and we'd be lucky to see it start this year. This is one more hazard of Dendreon not signing at least an ex-US partnership -- lack of management bandwidth to focus on their pipeline.

In theory, the should be able to use already licened antigen targets to duplicate Provenge success. The cassette technology, monoantigen focus, and semi-autologous approach should translate well to other tumors with a history of response to immune therapy. Bladder is a good first choice, though some question whether her2-neu is the best target.